Depomed — Proxy Contest (November 2015)
28 slides from Depomed's proxy contest presentation, Nov 18, 2015
Slide 1: Forward-Looking Statements
Forward-Looking Statements The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s acquisitions of the NUCYNTA® franchise in the United States and cebrano
Slide 2: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
November 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (1) Track Record of Accelerated Growth Organic growth - success increasing product sales, sc
Slide 3: Depomed's Track Record of Successful Deals Builds Value
Reworked Santarus deal and tripled net revenue 29% revenue growth Q3 2015 over Q3 2014 Acquired Q4 2013; relaunched Q1 2014; 21% revenue growth Q3 2015 over Q3 2014 Q3 2011 Q4 2011 Q4 2013 TYPE 2 DIABETES DEAL Non-strategic milestones & royalties sold for $240 million Q4 2013 Relaunch Q4 2013 follow
Slide 4: Depomed's "Acquire, Integrate, Grow" Business Model Driving An Accelerated Growth Cycle
Depomed’s “Acquire, Integrate, Grow” Business Model Driving An Accelerated Growth Cycle 5 November 2015 ACQUIRE Pain and neurology products with lengthy exclusivity and peak sales ahead INTEGRATE Speed and efficiency from playbook based on past success with same team GROW Repositioning and marketing
Slide 5: Cebranopadol – Late-Stage, Novel, First-in-Class Potent Analgesic
November 2015 Cebranopadol – Late-Stage, Novel, First-in-Class Potent Analgesic Novel, First-In-Class Asset Builds on Depomed’s leading position in pain and neurology Unique dual mechanism-of-action that incorporates novel pharmacology: nociceptin (NOP) receptor agonist activity Treatment of moderat
Slide 6: Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability
Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability $500K $27.1M $58.1M $114M $336M-348 (1) November 2015 2015 Total Product Sales Guidance (Includes NUCYNTA starting April 2, 2015) Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $112M At M
Slide 7: Depomed's Clear Track Record of Value Creation
Depomed’s Clear Track Record of Value Creation 9 November 2015 Depomed is in a Period of Significant Growth and We Believe is Well-Positioned for Future Success Source: Stock chart from BigCharts.com Covering 11/13/10 to 11/13/15. Includes period following Horizon’s initial public offer. Depomed doe
Slide 8: Depomed 3Q 2015 - Continued Strong Performance With Record Sales and Cash Flow
Depomed 3Q 2015 - Continued Strong Performance With Record Sales and Cash Flow – Product Sales Up 242% Over Prior Year 10 November 2015 Record Quarterly Results 2015 Guidance Updated* Additional Highlights Net product sales of $105M (242% over Q3 2014) Added $52M of cash in third quarter Product sal
Slide 9: Depomed Expected to be a Top 5 Branded Pain Company by 2016
11 11 November 2015 Acute Pain Breakthrough Cancer Pain Chronic Pain Neuropathic Pain Migraine ü ü ü ü ü ü ü ü ü ü ü ü ü ü Source: Depomed Marketing, company websites Depomed Expected to be a Top 5 Branded Pain Company by 2016 ü We Believe Depomed is Building the Most Complete Pain Portfolio in the
Slide 10: NUCYNTA: Potential to Exceed $1 Billion in Sales
NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story – Blockbuster Potential (1) Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Competes in multi-billion dollar pain market Exclusivity expected for a
Slide 11: Depomed's NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales
Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales (1) November 2015 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strategie
Slide 12: Promotion: Significantly Increased to Drive Prescriptions and Market Share
Promotion: Significantly Increased to Drive Prescriptions and Market Share 14 November 2015 Increased Sales Force 1 Optimized Medical Education Identifying Appropriate Target Prescribers Promotion strategy consists of: 3-fold increase to 277 reps Highly experienced in pain and neurology Resumed full
Slide 13: Promotion Progress: Accelerating Demand - Rx Growth of 14.6% Over Prior Year
Sales force delivering approximately 10k NUCYNTA calls per week since re-launch PAINWeek® 2015 1,000+ attendees at NUCYNTA and CME-sponsored symposia Speaker Program Education: early focus and success 710 attendees on 7/30 national webcast; >200 high decile targets 850+ programs targeted for 2015 Ye
Slide 14: Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain
Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain 16 November 2015 Chronic pain affects 1/3 of the US population More than 100 million adults with chronic pain 31 million with chronic lower back pain (CLBP) Potential significant impact from even modest uptic
Slide 15: Positioning Progress: Market Share Increased From 1.49% to 1.70% Since Re-Launch
Competes in >$5 billion dollar Long Acting Opioid (LAO) market Increased promotional activities with new messaging resonating with prescribers Key opinion leaders educating on potential dual mechanism and titration Market share of LAO market up .21 in just 4 months 17 November 2015 Positioning Progr
Slide 16: Pricing and Access: Maximizing Brand Through Pricing and Access Strategies
Pricing and Access: Maximizing Brand Through Pricing and Access Strategies 18 November 2015 94% of commercial lives have access to NUCYNTA and NUCYNTA ER United Healthcare Commercial moved NUCYNTA ER in front of Oxycontin on formulary as of July 1, 2015 Oxycontin removed from Tier 2 and now requires
Slide 17: Proper Dosing: Education on Titration is Key
Proper Dosing: Education on Titration is Key Average dose in low back pain trials was ~400mg/day after titration 19 November 2015 4 200 mg Proper Dose May Improve Physician and Patient Experience as well as Increase Average Selling Price Expert Opin. Pharmacother. (2010) 11(11):1787-1804 250 mg ~400
Slide 18: NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More
NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More (1) November 2015 NUCYNTA >$500MM by 2018 and $1 Billion Before Patent Expiry (2) February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of polym
Slide 19: Depomed's Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA
November 2015 Depomed’s Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA Product Differentiation 3Q Annualized Revenues Revenue Growth Over 3Q 2014 Expected Exclusivity (1) 1x daily with less dizziness and somnolence $84M 29% April 2015 ANDA settlement provides exclusivity to
Slide 20: Depomed Sales Force Effectively Targets Key Specialties
Depomed Sales Force Effectively Targets Key Specialties Core Sales Force n=277 Cancer Pain Specialists n=24 Pain Focused Neurology Focused 22 November 2015
Slide 21: Depomed's Ability to Efficiently Execute and Deliver Growth - Gralise
November 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in Q4 2011 >$84 million run rate as of Q3 2015 Market exclusivity expected until 2024; won District Court decision vs. first filer, Actavis; a
Slide 22: Depomed's Ability to Efficiently Execute and Deliver Growth - CAMBIA
November 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in Q1 2014 $28 million run rate as of Q3 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults Exclusivi
Slide 23: Depomed's Ability to Efficiently Execute and Deliver Growth - Lazanda
November 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Lazanda Acquired in July 2013 for $4M Relaunched in Q4 2013 $22 million run rate as of Q3 2015 Net sales has more than doubled in last 12 months and 4x since relaunch Effective January 1st, only branded rapid acting fentanyl
Slide 24: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time
Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time November 2015 Securing Market Exclusivity for Depomed Products Well Into Next Decade (1) Product Expected Exclusivity 2028 Acquired April 2015; composition of matter patent to 2022/2023; polymorph and method of
Slide 25: Acquire, Integrate and Grow Strategy will Continue to Create Value
November 2015 We Expect Depomed’s Acquire, Integrate and Grow Strategy will Continue to Create Value Maintain pain and neurology focus, leveraging management’s expertise Products with current annual revenue between $20-$200MM+ Targeting products with lengthy exclusivity and future peak sales Rapid D
Slide 26: Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade
Depomed’s Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade IP Litigation Potential future cash flow from IP litigation against Purdue Pharma PTAB has confirmed the patentability of each of the 25 claims subject to Purdue IPRs 20% of 560 PTAB decisions through Q3 2
Slide 27: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
November 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (1) Track Record of Accelerated Growth Organic growth - success increasing product sales, sc
Slide 28: Thank You
pve KS < Depomed Thank You www.depomed.com